CD8A and myeloid sarcoma: Thus, the key question is whether clonally expanded CD8+ TEMRA cells in AD, PD, or MS are immune-suppressive regulatory cells that kill pathogenic CD4+ T cells, or they are proinflammatory cytolytic cells that fuel neurodegeneration.